XNASBNGO
Market cap27mUSD
Jan 17, Last price
0.19USD
1D
-5.60%
1Q
-41.79%
IPO
-99.72%
Name
Bionano Genomics Inc
Chart & Performance
P/E
—
P/S
0.75
EPS
—
Div Yield, %
%
Shrs. gr., 5y
117.12%
Rev. gr., 5y
24.65%
Revenues
36m
+29.90%
Net income
-232m
L+75.34%
CFO
-125m
L+0.29%
Earnings
Mar 03, 2025
Profile
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 36,116 29.90% | 27,802 54.62% | ||||||
Cost of revenue | 80,582 | 70,904 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (44,466) | (43,102) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 62 | 1,884 | ||||||
Tax Rate | ||||||||
NOPAT | (44,528) | (44,986) | ||||||
Net income | (232,493) 75.34% | (132,596) 83.06% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 57,697 | 23,128 | ||||||
BB yield | -89.39% | -54.77% | ||||||
| Debt | ||||||||
Debt current | 72,238 | 2,545 | ||||||
Long-term debt | 16,785 | 20,791 | ||||||
Deferred revenue | 154 | 127 | ||||||
Other long-term liabilities | 10,890 | 12,970 | ||||||
Net debt | (13,265) | (90,250) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (125,181) | (124,816) | ||||||
CAPEX | (1,691) | (3,302) | ||||||
Cash from investing activities | 24,158 | 82,767 | ||||||
Cash from financing activities | 113,815 | 23,007 | ||||||
FCF | (50,247) | (62,054) | ||||||
| Balance | ||||||||
Cash | 101,888 | 113,186 | ||||||
Long term investments | 400 | 400 | ||||||
Excess cash | 100,482 | 112,196 | ||||||
Stockholders' equity | (581,180) | (349,809) | ||||||
Invested Capital | 767,794 | 623,147 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 34,150 | 28,921 | ||||||
Price | 1.89 29.45% | 1.46 -51.17% | ||||||
Market cap | 64,544 52.86% | 42,225 -48.98% | ||||||
EV | 51,278 | (48,025) | ||||||
EBITDA | (30,554) | (33,262) | ||||||
EV/EBITDA | 1.44 | |||||||
Interest | 5,119 | 298 | ||||||
Interest/NOPBT | ||||||||